Shopping Cart
Remove All
Your shopping cart is currently empty
PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $46 | In Stock | In Stock | |
| 5 mg | $109 | In Stock | In Stock | |
| 10 mg | $178 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $678 | In Stock | In Stock | |
| 100 mg | $995 | - | In Stock | |
| 500 mg | $2,160 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $107 | In Stock | In Stock |
| Description | PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia. |
| Targets&IC50 | α7 nAChR:8.8 nM (Ki) |
| In vivo | In rats, PHA-543613 (0.3 mg/kg) reverses Scopolamine-induced short-term memory deficits[2]. Intraperitoneal injection of PHA-543613 (4 and 12 mg/kg) increases p-Akt and decreases p-GSK-3 and CC3 expressions in the ipsilateral hemisphere. PHA-543613 reduces neuronal cell death in the perihematomal area[3]. |
| Molecular Weight | 271.31 |
| Formula | C15H17N3O2 |
| Cas No. | 478149-53-0 |
| Smiles | O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1 |
| Relative Density. | 1.32 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 225 mg/mL (829.31 mM), Sonication is recommended. H2O: < 30.78 mg/mL, Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.